The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid shifting dynamics in the medical device sector, Boston Scientific is facing headwinds following significant analyst revisions. Piper Sandler maintained its Overweight rating on the stock but slashed its price target from $90 to $65, while BTIG similarly lowered its target to $65 while keeping a Buy rating. These adjustments stem from concerns over slowing sales growth in the Watchman product line and reduced visibility regarding the company's performance through the second and third quarters of 2026.
This downward revision contrasts with some industry peers; for instance, Medtronic reported a steady 5.2% revenue growth in its most recent fiscal quarter per market data, highlighting specific challenges for Boston Scientific's market share in cardiac technologies. Analysts suggest that while long-term recovery is expected by 2027, the near-term outlook remains clouded by execution risks and competitive pressures in the structural heart market.
Sign in to access this content
Sign InBSX shares stood at $45.29 at close June 18, 2026, trading significantly below the revised $65 targets but remaining sensitive to the recent low of $44.44. Investors should monitor upcoming macroeconomic catalysts, including U.S. retail sales data and the broader impact of the Federal Reserve's interest rate path on healthcare capital spending and consumer medical demand.